IDs are a wide range of conditions driven by Chronic Inflammatory (CI) processes. They encompass most chronic Non-Communicable Diseases (NCDs) such as cardiovascular conditions, cancers, diabetes, arthritis, neurodegenerative disorders, and bowel diseases. Chronic Inflammatory Diseases (CIDs) are a major cause of sickness and premature death globally.
0
Bn
of the
0
Bn
humans currently alive are expected to get sick and die due to a CIDs.
The World Economic Forum estimates that the global costs of just four chronic diseases –cancer, diabetes, heart disease and respiratory disease – will reach
$
0
trillion by 2030
From late action
To early diagnostic and prevention
The World Economic Forum estimates that the global costs of just four chronic diseases –cancer,diabetes, heart disease and respiratory disease –will reach $47 trillion by 2030
All these conditions are characterised by CI processes and there are no reliable, prognostic biomarkers to measure it.
Medics diagnose Chronic Inflammatory Diseases only after tissue and organ damage has occurred and are unable to reliably identify the most vulnerable patients to prevent development of the disease at the early stage.
For many syndromic IDs, medics cannot readily distinguish between the different possible types of immune dysfunction, so they use imprecise therapies that alleviate symptoms rather than identify and treat causes.
From imprecision
To personalised treatment solutions
From expensive
To affordable and accessible to all
The lack of affordable and scalable prognostic and predictive tests leads to mounting healthcare costs. Patients with the worst health outcomes are only identified when they have serious inflammatory episodes. Hence costs to treat them are significantly higher.
FROM LATE ACTION
TO DIAGNOSTIC AND PREVENTION
Medics diagnose Chronic Inflammatory Diseases only after tissue and organ damage has occurred and are unable to reliably identify the most vulnerable patients to prevent development of the disease at the early stage.
FROM IMPRECISION
TO PERSONALISED TREATMENT SOLUTIONS
For many syndromic IDs, medics cannot readily distinguish between the different possible types of immune dysfunction, so they use imprecise therapies that alleviate symptoms rather than identify and treat causes.
FROM EXPENSIVE
To affordable and accessible to all
The lack of affordable and scalable prognostic and predictive tests leads to mounting healthcare costs. Patients with the worst health outcomes are only identified when they have serious inflammatory episodes. Hence costs to treat them are significantly higher.
Vision
To develop safe, effective, and affordable personalised precision healthcare solutions for inflammatory diseases to improve individuals’ overall quality of life.
Mission
ITo develop fast-track diagnostic tools and treatments for those vulnerable to inflammatory diseases. Avenna aims to improve healthspan and reduce healthcare costs to enable individuals to lead longer, healthier, and happier lifestyles. Our med term focus surrounds precision healthcare biomarkers for inflammatory bowel, brain, and skin diseases.
Our Story
Avenna was founded in 2017 to translate a promising glycomic research programme conducted by its sister company, Ludger, into practical, and affordable diagnostic tools for inflammatory diseases. We are now working with different members within the healthcare ecosystem including scientists, clinicians, academics and patient groups, to further translate this assay into clinical biomarkers.
Avenna translates and transforms promising research programmes into practical, affordable, and accessible tools tailored to inflammatory diseases, for personal, public, and clinical use.